289686-73-3

Usage

Uses

Used in Pharmaceutical Industry:
(RS)-α-Methyl-3,5-bis(trifluoromethyl)benzeneacetic Acid is used as a nonsteroidal anti-inflammatory drug (NSAID) for its ability to alleviate pain, inflammation, and other symptoms associated with conditions such as arthritis, gout, and musculoskeletal disorders. Its mode of action involves inhibiting the production of prostaglandins, which are crucial in the inflammatory response.
Additionally, while effective, (RS)-α-Methyl-3,5-bis(trifluoromethyl)benzeneacetic Acid may also cause side effects like gastrointestinal irritation and an increased risk of cardiovascular events. As a result, its use is carefully considered in relation to the potential benefits and risks for each patient.

Upstream product

• 374794-36-2 2-(3,5-bistrifluoromethylphenyl)methyl propionate 
• 374794-55-5 dicyclohexylammonium (RS)-α-methyl-3,5-bis(trifluoromethyl)benzeneacetate 
• 124-38-9 carbon dioxide 
• 349-59-7 3,5-bis(trifluoromethyl)styrene 
• 85068-33-3 3,5-bistrifluoromethylphenyl acetic acid 
• 74-88-4 methyl iodide 

Downstream Products

• 1161355-29-8 2-(3,5-bis(trifluoromethyl)phenyl)-N-(4-(2-methylpyridin-4-yl)phenyl)propanamide 
• 374794-55-5 dicyclohexylammonium (RS)-α-methyl-3,5-bis(trifluoromethyl)benzeneacetate 
• 374791-10-3 (RS)-α-methyl-N-[4-oxo-1-phenylcyclohexyl]-3,5-bis(trifluoromethyl)benzeneacetamide 

Relevant academic research and scientific papers

Construction of a visible light-driven hydrocarboxylation cycle of alkenes by the combined use of Rh(i) and photoredox catalysts

A visible light driven catalytic cycle for hydrocarboxylation of alkenes with CO2 was established using a combination of a Rh(i) complex as a carboxylation catalyst and [Ru(bpy)3]2+ (bpy = 2,2′- bipyridyl) as a photoredox catalyst. Two key steps, the generation of Rh(i) hydride species and nucleophilic addition of π-benzyl Rh(i) species to CO2, were found to be mediated by light.

PIPERIDINE COMPOUND AND PROCESS FOR PREPARING THE SAME

The present invention is to provide a piperidine compound represented by the formula [I]: wherein Ring A is an optionally substituted benzene ring, Ring B is an optionally substituted benzene ring, R1 is hydrogen atom or a substituent for amino group, R2 is hydrogen atom, an optionally substituted hydroxyl group, an optionally substituted amino group, an optionally substituted alkyl group, a substituted carbonyl group or a halogen atom, Z is oxygen atom or -N(R3)-, R3 is hydrogen atom or an optionally substituted alkyl group, R4a and R4b may be the same or different, and each is hydrogen atom or an optionally substituted alkyl group, or a pharmaceutically acceptable salt thereof, which has an excellent tachykinin receptor antagonistic action.

Efficient synthesis of novel NK1 receptor antagonists: Selective 1,4-addition of Grignard reagents to 6-chloronicotinic acid derivatives

A new efficient synthesis of two novel classes of NK1 receptor antagonists, among them befetupitant and netupitant, starting from 6-chloronicotinic acid is described. The introduction of the o-tolyl substituent at C(4) of the pyridine ring was achieved by a one-pot selective 1,4-Grignard addition/oxidation sequence to 6-chloronicotinic acid or a derivative of it. The scope of this addition/oxidation sequence was examined. It was also shown that the carboxylic function can be converted to a methyl amino group by a Hofmann rearrangement followed by reduction. Furthermore, a new high-yielding synthesis of 2-(3,5-bistrifluoromethylphenyl)-2-methyl propionic acid based on the carbonylation of the tertiary alcohol obtained by Grignard addition of 3,5-bis(trifluoromethyl)bromobenzene to acetone was established.

Cyclohexane derivatives and their use as therapeutic agents

The present invention relates compounds of formula (I), wherein ring A is a phenyl or pyridyl ring; X represents a linker selected from the group consisting of formulae: (a), (b), (c), (d), and (e); and R1, R2, R3, R4, R5, R6, R7, R13, R14, R15, R16, R17, R21a and R21b are as defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpetic neuralgia.